The DSHEA-Patent Squeeze: Method-of-Use Patents and Regulatory Barriers (automated near-duplicate probe)

Abstract

When a pharmaceutical company files a method-of-use patent on a new therapeutic application of a compound already sold over-the-counter as a dietary supplement, the patent interacts with the DSHEA drug preclusion clause FD&C Act 201(ff)(3)(B) and FDA exclusivity grants to create access friction. This essay intentionally shortens existing Pubroot coverage by removing tables and several case-study paragraphs while recycling the same statutory hooks and examples (colchicine, N-acetylcysteine). No new empirical datasets or legal analysis are offered. Purpose: verify whether the live Gemini review scores this below the 6.0 acceptance threshold for original research due to low novelty.

Why this issue exists

This submission is an automated pressure test issued from CI tooling. It is meant to overlap lexically and thematically with 2026-005 so Stage 2 can flag potential supersession and Stage 5 must judge novelty. Maintainers may close the issue after reading the workflow result; please do not treat this as a serious new research claim.

Introduction

Method-of-use patents under 35 U.S.C. can run for many years. FDA regulatory exclusivity is shorter. DSHEA preclusion can matter when a compound was approved as a drug before supplement marketing. The combination can raise prices and restrict how firms communicate uses. This version repeats those mechanisms in fewer words than essay 2026-005.

Mechanism

FDA exclusivity rewards clinical trials. Patents add enforcement beyond exclusivity. DSHEA section 201(ff)(3)(B) is the statutory hook discussed in the longer essay. The patent layer is sometimes addressable with prior art publication. Exclusivity and statute are harder to move without legislative change. Method-of-use patents amplify regulatory barriers to public-domain compounds by stretching commercial control.

Case snapshots

Colchicine illustrates large price increases after exclusivity plus patents. N-acetylcysteine illustrates FDA warning letters and supplement market tension. Detailed aptamer discussion and comparison tables from the canonical essay are omitted here on purpose so overlap is obvious.

Regulatory barriers

FDA marketing exclusivity transforms temporary exclusivity into longer monopoly control when patents overlap. Dietary supplement status interacts with drug preclusion. Compounding restriction on public access is the policy concern repeated here without new evidence.

Conclusion

This draft is a deliberate near-duplicate for pipeline testing. Under original-research criteria, novelty should be scored critically relative to existing Pubroot work 2026-005 and mainstream commentary.